Abstract:Induction of PD‐L1 by E6 oncoprotein or mutant EGFR through the ERK‐C/EBPβ‐TLR4‐NF‐κB cascade may promote tumor growth and invasiveness in NSCLC because of decreasing TGF‐β1 and SMAD4 expression. Therefore, we suggest anti‐PD‐L1 immunotherapy combined with MEK/ERK inhibitors might show a clinical benefit as a treatment for NSCLC, particularly in patients with E6‐positive and/or EGFR mutant tumors.BackgroundProgrammed death ligand‐1 (PD‐L1) has a known association with the prognosis of human cancers because of its ability to alter tumor immune surveillance via its interaction with PD‐1. We questioned whether expression of PD‐L1 in tumor cells could directly promote tumor growth and invasiveness in non–small cell lung cancer (NSCLC).MethodsReal‐time reverse transcription‐polymerase chain reaction (RT‐PCR) was performed to evaluate PD‐L1 messenger RNA (mRNA) expression in lung tumors. The prognostic value of PD‐L1 mRNA was assessed by Cox regression model. Transcriptional regulation of PD‐L1 by human papillomavirus (HPV) 16/18 E6 oncoprotein or by epidermal growth factor receptor (EGFR) mutation in lung cancer cells was examined by Western blot and luciferase reporter assay. The cell growth and invasion were evaluated by colony formation, soft agar growth, and Boyden chamber assay.ResultsThe PD‐L1 mRNA levels showed a positive association with HPV 16/18 E6 oncoprotein and with EGFR mutation in 223 surgically resected NSCLC patients. The prognostic significance of PD‐L1 was more commonly observed in patients with high PD‐L1/E6 positive and high PD‐L1/EGFR mutant tumors. Mechanistically, upregulation of PD‐L1 transcription by E6 or mutant EGFR occurred largely through the ERK‐C/EBPβ‐TLR4‐NF‐κB cascade. PD‐L1 promotes the efficacy of colony formation, soft agar growth, and cell invasion. PD‐L1 upregulates BAG‐1 to reduce transforming growth factor (TGF)‐β1 expression, and the decrease in SMAD4 because of TGF‐β1 occurs through the p53/microRNA (miR)‐224 axis. The decreases in TGF‐β1 and SMAD4 are responsible for PD‐L1‐mediated cell invasiveness.ConclusionInduction of PD‐L1 by E6 oncoprotein or mutant EGFR through the ERK‐C/EBPβ‐TLR4‐NF‐κB cascade may promote tumor growth and invasiveness in NSCLC because of decreasing TGF‐β1 and SMAD4 expression.

Pd-L1 Promotes Tumor Growth And Progression By Activating Wip And Beta-Catenin Signaling Pathways And Predicts Poor Prognosis In Lung Cancer

PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer

Wnt5b-induced PCP/JNK Activation Promotes PD-L1 Expression and the Malignant Phenotype of Non-small Cell Lung Cancer

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Beta-Catenin Induces Transcriptional Expression Of Pd-L1 To Promote Glioblastoma Immune Evasion

PD‐L1 expressed from tumor cells promotes tumor growth and invasion in lung cancer via modulating TGF ‐β1/ SMAD4 expression

PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.

PD‐L1 Positively Regulates MET Phosphorylation Through Inhibiting PTP1B

Co-expression of PD-L1 and HIF-1α Predicts Poor Prognosis in Patients with Non-small Cell Lung Cancer after Surgery.

Β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells

Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma.

WT1‐interacting Protein Inhibits Cell Proliferation and Tumorigenicity in Non‐small‐cell Lung Cancer Via the AKT/FOXO1 Axis

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

Wilms’ tumour suppressor gene 1 (WT1) is involved in the carcinogenesis of Lung cancer through interaction with PI3K/Akt pathway

EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells

POC1A promotes lung adenocarcinoma progression through the PI3K/AKT pathway and is a potential prognostic marker

PD-L1 Interacts with Frizzled 6 to Activate Β-Catenin and Form a Positive Feedback Loop to Promote Cancer Stem Cell Expansion

Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.

Role of hypoxia-inducible factor-1α in the regulation of programmed death ligand 1 expression in lung adenocarcinoma